{"protocolSection": {"identificationModule": {"nctId": "NCT00809757", "orgStudyIdInfo": {"id": "051-359"}, "organization": {"fullName": "Sumitomo Pharma America, Inc.", "class": "INDUSTRY"}, "briefTitle": "A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma", "officialTitle": "A Safety, Efficacy, and Tolerability Study of Daily Dosing With Levalbuterol Tartrate HFA MDI and Placebo in Subjects Aged Birth to <48 Months With Asthma"}, "statusModule": {"statusVerifiedDate": "2014-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-12"}, "primaryCompletionDateStruct": {"date": "2013-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-12-15", "studyFirstSubmitQcDate": "2008-12-16", "studyFirstPostDateStruct": {"date": "2008-12-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-05-27", "resultsFirstSubmitQcDate": "2014-07-01", "resultsFirstPostDateStruct": {"date": "2014-07-28", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-07-01", "lastUpdatePostDateStruct": {"date": "2014-07-28", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sumitomo Pharma America, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "A Safety, Efficacy, and Tolerability Study of Daily Dosing with Levalbuterol Tartrate HFA MDI and Placebo in Subjects Aged Birth to \\<48 Months with Asthma.", "detailedDescription": "This is a modified-blind, randomized, placebo-controlled, multicenter, parallel-group trial of levalbuterol HFA MDI administered using a facemask and holding chamber in subjects birth to \\<48 months with asthma. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 197, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "90 ug Levalbuterol (2 actuations)", "interventionNames": ["Drug: Levalbuterol"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "0.31 ug Levalbuterol UDV TID", "interventionNames": ["Drug: Levalbuterol UDV TID"]}, {"label": "3", "type": "PLACEBO_COMPARATOR", "description": "Placebo", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Levalbuterol", "description": "90 ug Levalbuterol (2 actuations)", "armGroupLabels": ["1"], "otherNames": ["Xopenex HFA Inhalation Aerosol"]}, {"type": "DRUG", "name": "Levalbuterol UDV TID", "description": "0.31 ug Levalbuterol UDV TID", "armGroupLabels": ["2"], "otherNames": ["Xopenex Inhalation Solution"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo (2 actuations)", "armGroupLabels": ["3"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline to Visit 4 in the Mean Daily Composite Score Based on the Pediatric Asthma Caregiver Assessments (PACA)", "description": "The daily composite score is the sum of the scores of 5 domains: Nocturnal Awakenings Due to Wheeze and Cough, Daytime Wheeze, Daytime Cough, Shortness of Breath, and Asthma Symptom Score. A possible score of 0 (no symptoms) to 19 (severe symptoms).\n\nThe mean daily composite score at Visit 4 is defined as the mean of the daily composite scores in the week prior to Visit 4.", "timeFrame": "Baseline, Visit 4 (Week 4)"}], "secondaryOutcomes": [{"measure": "Change From Baseline to Visit 3 in Mean Daily Composite Score Based on the Pediatric Asthma Caregiver Assessment", "description": "The daily composite score is the sum of the scores of 5 domains: Nocturnal Awakenings Due to Wheeze and Cough, Daytime Wheeze, Daytime Cough, Shortness of Breath, and Asthma Symptom Score. A possible score of 0 (no symptoms) to 19 (severe symptoms).\n\nThe mean daily composite score at Visit 3 is defined as the mean of the daily composite scores in the 7 days prior to Visit 3.", "timeFrame": "Baseline, Visit 3 (Week 3)"}, {"measure": "Change From Baseline to Visit 2 to Visit 3 in the Mean Daily Composite Score Based on the Pediatric Asthma Caregiver Assessment", "description": "The daily composite score is the sum of the scores of 5 domains: Nocturnal Awakenings Due to Wheeze and Cough, Daytime Wheeze, Daytime Cough, Shortness of Breath, and Asthma Symptom Score. A possible score of 0 (no symptoms) to 19 (severe symptoms).\n\nThe mean daily composite score from Visit 2 to Visit 3 is defined as the mean of the daily composite scores from Visit 2 (inclusive) to the day prior to Visit 3.", "timeFrame": "The days from Visit 2 (inclusive) to the day prior to Visit 3 - approximately 14 days"}, {"measure": "Change From Baseline to Visit 3 to Visit 4 in the Mean Daily Composite Score Based on the Pediatric Asthma Caregiver Assessment", "description": "The daily composite score is the sum of the scores of 5 domains: Nocturnal Awakenings Due to Wheeze and Cough, Daytime Wheeze, Daytime Cough, Shortness of Breath, and Asthma Symptom Score. A possible score of 0 (no symptoms) to 19 (severe symptoms).\n\nThe mean daily composite score from Visit 3 to Visit 4 is defined as the mean of the daily composite scores from Visit 3 (inclusive) to the day prior to Visit 4.", "timeFrame": "The days from Visit 3 (inclusive) to the day prior to Visit 4 - approximately 14 days"}, {"measure": "Change From Baseline to Visit 3 in the Mean Daily Composite Score Based on the Daytime and Nighttime Asthma Symptom Scores as Measured by the Pediatric Asthma Questionnaire (PAQ)", "description": "The daily composite score is the sum of the scores of 7 items: Difficulty Breathing, Cough, Wheeze, Activity Limitation, Level of Activity Limitation, Overall Symptom Score, and Nighttime Asthma. The range for the PAQ is 0 (no symptoms) to 27 (severe symptoms).\n\nThe mean daily composite score at Visit 3 is defined as the mean daily composite scores for 7 days prior to Visit 3.", "timeFrame": "Baseline, Visit 3 (Week 3)"}, {"measure": "Change From Baseline to Visit 4 in the Mean Daily Composite Score Based on the Daytime and Nighttime Asthma Symptom Scores as Measured by Pediatric Asthma Questionnaire", "description": "The daily composite score is the sum of the scores of 7 items: Difficulty Breathing, Cough, Wheeze, Activity Limitation, Level of Activity Limitation, Overall Symptom Score, and Nighttime Asthma. The range for the PAQ is 0 (no symptoms) to 27 (severe symptoms).\n\nThe mean daily composite score at Visit 4 is defined as the mean daily composite scores in the 7 days prior to Visit 4.", "timeFrame": "Baseline, Visit 4 (Week 4)"}, {"measure": "Change From Baseline to Visit 2 to Visit 3 in the Mean Daily Composite Score Based on the Daytime and Nighttime Asthma Symptom Scores as Measured by the Pediatric Asthma Questionnaire", "description": "The daily composite score is the sum of the scores of 7 items: Difficulty Breathing, Cough, Wheeze, Activity Limitation, Level of Activity Limitation, Overall Symptom Score, and Nighttime Asthma. The range for the PAQ is 0 (no symptoms) to 27 (severe symptoms).\n\nThe mean daily composite score from Visit 2 to Visit 3 is defined as the mean of the daily composite scores from Visit 2 (inclusive) to the day prior to Visit 3.", "timeFrame": "The days from Visit 2 (inclusive) to the day prior to Visit 3 - approximately 14 days"}, {"measure": "Change From Baseline to Visit 3 to Visit 4 in the Mean Daily Composite Score Based on the Daytime and Nighttime Asthma Symptom Score as Measured by the Pediatric Asthma Questionnaire", "description": "The daily composite score is the sum of the scores of 7 items: Difficulty Breathing, Cough, Wheeze, Activity Limitation, Level of Activity Limitation, Overall Symptom Score, and Nighttime Asthma. The range for the PAQ is 0 (no symptoms) to 27 (severe symptoms).\n\nThe mean daily composite score from Visit 3 to Visit 4 is defined as the mean of the daily composite scores from Visit 3 (inclusive) to the day prior to Visit 4.", "timeFrame": "The days from Visit 3 (inclusive) to the day prior to Visit 4 - approximately 14 days"}, {"measure": "Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoints at Visit 2", "description": "Peak expiratory flow (PEF) measures how fast a person can breathe out using the greatest effort", "timeFrame": "Baseline, Visit 2: 30 minutes post-dose (on the day of randomization), 1 hour post-dose, 4 hours post-dose, 6 hours post-dose"}, {"measure": "Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoint at Visit 3", "timeFrame": "Baseline, Visit 3, pre-dose (approximately 14 days after randomization)"}, {"measure": "Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoint at Visit 4", "timeFrame": "Visit 4: pre-dose (approximately 28 days after randomization) , 30 minutes post-dose, 1 hour post-dose, 4 hours post-dose, 6 hours post-dose"}, {"measure": "Percent Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoints at Visit 2", "timeFrame": "Baseline, Visit 2: , 30 minutes post-dose (on the day of randomization), 1 hour post-dose, 4 hours post-dose, 6 hours post-dose"}, {"measure": "Percent Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoints at Visit 3", "timeFrame": "Baseline, Visit 3, pre -dose (approximately 14 days after randomization)"}, {"measure": "Percent Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoints at Visit 4", "timeFrame": "Baseline, Visit 4, pre -dose (approximately 28 days after randomization)"}, {"measure": "Change From Baseline in the At-Home Mean Daily Peak Expiratory Flow (PEF to Postdose Timepoint at Visit 3 and Visit 4", "description": "Mean of the daily pre-dose PEF values in the week prior to visit in those subjects aged 24 to \\<48 months capable of performing acceptable and reproducible PEF maneuvers.", "timeFrame": "Baseline, Visit 3 (the week prior to Visit 3) and Visit 4"}, {"measure": "Percent Change From Baseline in the At-Home Mean Daily Peak Expiratory Flow (PEF to Postdose Timepoint at Visit 3 and Visit 4)", "description": "Mean of the daily pre-dose PEF values in the week prior to visit in those subjects aged 24 to \\<48 months capable of performing acceptable and reproducible PEF maneuvers.", "timeFrame": "Visit 3 (the week prior to Visit 3), Visit 4 (the week prior to Visit 4)"}, {"measure": "Investigator Global Assessment - Question 1", "description": "Since the start of the study, how would you evaluate the child's asthma symptoms?", "timeFrame": "Visit 4 (End of 28 day treatment period)"}, {"measure": "Investigator Global Assessment - Question 2", "description": "Since the start of the study, how would you evaluate your ability to manage the subject's asthma?", "timeFrame": "Visit 4 (End of 28 day treatment period)"}, {"measure": "Caregiver Global Assessment - Question 1", "description": "Since the start of the study, how would you evaluate your child's asthma symptoms?", "timeFrame": "Visit 4 (End of 28 day treatment period)"}, {"measure": "Caregiver Global Assessment - Question 2", "description": "Since the start of the study, how would you evaluate your ability to manage your child's asthma?", "timeFrame": "Visit 4 (End of 28 day treatment period)"}, {"measure": "Caregiver Global Assessment - Question 3", "description": "Overall I was: Very satisfied with the control of the child's asthma symptoms while enrolled in this study, Moderately satisfied with the control of the child's asthma symptoms while enrolled in this study, Slightly satisfied with the control of the child's asthma symptoms while enrolled in this study, Not satisfied with the control of the child's asthma symptoms while enrolled in this study or answer Missing", "timeFrame": "Visit 4 (End of 28 day treatment period)"}, {"measure": "Rescue Medication Use: Number of Subjects Using Rescue Medication During the Treatment Period", "description": "Number of subjects using rescue medication during the treatment period", "timeFrame": "Visit 2 to Visit 3 (the first 2 weeks of the study) , Visit 3 to Visit 4 (the second 2 weeks of the study), Visit 2 to Visit 4 (the entire 4 weeks of the study)"}, {"measure": "Rescue Medication Use - Change From Baseline in Mean Number of Days Used Per Week When Used", "timeFrame": "Visit 2 to Visit 3 (the first 2 weeks of the study) , Visit 3 to Visit 4 (the second 2 weeks of the study), Visit 2 to Visit 4 (the entire 4 weeks of the study)"}, {"measure": "Rescue Medication Use - Change From Baseline in Mean Number of Doses Used Per Week", "timeFrame": "Visit 2 to Visit 3 (the first 2 weeks of the study) , Visit 3 to Visit 4 (the second 2 weeks of the study), Visit 2 to Visit 4 (the entire 4 weeks of the study)"}, {"measure": "Rescue Medication Use - Change From Baseline in Mean Number of Doses Used Per Week During Weeks When Used", "timeFrame": "Visit 2 to Visit 3 (the first 2 weeks of the study), Visit 3 to Visit 4 (the second 2 weeks of the study), Visit 2 to Visit 4 (the entire 4 weeks of the study)"}, {"measure": "Change From Baseline to Visit 3 and Visit 4 in the Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLA) Composite Score", "description": "The PACQLQ composite score was calculated as the mean of the scores of the 13 individual questions. Composite scores could range from 1 to 7. Lower scores indicated greater impact of disease on quality of life.", "timeFrame": "Visit 3 and Visit 4 (End of 28 day treatment period)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Subject's parent/legal guardian must give written informed consent, including privacy authorization, prior to study participation. Complete documentation regarding the consent process must be recorded in the case report form (CRF) and source documentation.\n* Subject's parent/legal guardian must be willing and able to comply with the study procedures and visit schedules.\n* Subject, male or female, must be between the ages of birth and \\<48 months, exclusive, at the time of consent.\n* Subjects 24 to \\<48 months of age must have a history of physician-diagnosed asthma (defined as at least 3 episodes of respiratory symptoms consistent with asthma symptoms including, but not limited to, cough, wheeze, or dyspnea).\n* Subjects 0 to \\<24 months of age must have a history of 3 episodes of respiratory symptoms that in the judgement of the investigator could be consistent with asthma or reactive airways disease.\n* Subject must be in good health and not affected by any other chronic conditions, including respiratory disorders other than asthma.\n* In subjects with a chest radiograph (taken 12 months prior to screening visit), no evidence of any chronic cardiopulmonary condition other than asthma should be present as discerned by the Investigator.\n* Subject's parent/legal guardian must be able to complete the diary cards and medical event calendars (MEC) reliably on a daily basis and understand dosing instructions and questionnaire completion.\n\nExclusion Criteria:\n\n* Subject who requires or is expected to require any disallowed medications\n* Subject who has participated in an investigational drug study within 30 days prior to screening, or who is currently participating in another clinical trial.\n* Subject or parent/legal guardian who has daily commitments during the study that would interfere with trial measurements, compliance, or both.\n* Subject who has a history of hospitalization for asthma, reactive airways disease, or bronchospasm within 4 weeks prior to screening or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial.\n* Subject who has experienced significant blood loss within 60 days of study drug.\n* Subject with a clinical diagnosis of cystic fibrosis.\n* Subject who was born prematurely, defined as less than 38 weeks gestational age at birth, and is \\<1 year of age at screening\n* Subject whose body weight is less than 7.0 kg at screening. This minimum weight requirement is based upon standard pediatric growth charts \\[CDC 2000\\].\n* Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations.\n* Subject using any prescription drug with which levalbuterol or racemic albuterol sulfate administration is contraindicated.\n* Subject with a history of life-threatening asthma, defined as previous asthma episodes requiring intubation or associated with hypercapnia, respiratory arrest, or hypoxic seizures.\n* Subject with clinically significant abnormalities that may interfere with the metabolism or excretion of the study drugs or study participation (eg, abnormalities of renal, hepatic, metabolic, or endocrine function).\n* Subject with a history of cancer.\n* Subject with any chronic or congenital cardiorespiratory condition other than asthma including, but not limited to, bronchopulmonary dysplasia, congenital heart disease, and cystic fibrosis.\n* Subject affected by an upper or lower respiratory tract infection in the 3 weeks prior to screening.\n* Subject with a history of ventilation for a respiratory condition occurring at or near birth, including those associated with prematurity or bronchopulmonary dysplasia. Ventilatory support for elective non-cardiopulmonary surgery is not exclusionary. - Subject with any clinically significant abnormal laboratory values (hematology, blood chemistry).\n* Subject with a clinically significant abnormal 12-lead ECG that would put the subject at risk for experiencing adverse cardiac effects.\n* Subject who is a relative of a staff member.", "healthyVolunteers": false, "sex": "ALL", "maximumAge": "48 Months", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Respiratory Medical Director, MD", "affiliation": "Sumitomo Pharma America, Inc.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Little Rock Allergy & Asthma Clinical Research Center", "city": "Little Rock", "state": "Arkansas", "zip": "72205", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "West Coast Clinical Trials, LLC", "city": "Cypress", "state": "California", "zip": "90630", "country": "United States", "geoPoint": {"lat": 33.81696, "lon": -118.03729}}, {"facility": "Allergy & Asthma Care Center of Southern California", "city": "Long Beach", "state": "California", "zip": "90808", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "Clinical Trials of Orange County, Inc.", "city": "Orange", "state": "California", "zip": "92868", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Allergy and Asthma Consultants", "city": "Redwood", "state": "California", "zip": "94063", "country": "United States", "geoPoint": {"lat": 37.48522, "lon": -122.23635}}, {"facility": "IMMUNOe International Research Centers", "city": "Centennial", "state": "Colorado", "zip": "80112", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "All Seasons Allergy and Asthma Center, P.A.", "city": "Fort Walton Beach", "state": "Florida", "zip": "32547", "country": "United States", "geoPoint": {"lat": 30.42077, "lon": -86.61939}}, {"facility": "Palm Beach Research Center", "city": "West Palm Beach", "state": "Florida", "zip": "33409", "country": "United States", "geoPoint": {"lat": 26.71534, "lon": -80.05337}}, {"facility": "Brookstone Centre Parkway", "city": "Columbus", "state": "Georgia", "zip": "31904", "country": "United States", "geoPoint": {"lat": 32.46098, "lon": -84.98771}}, {"facility": "Rush University Medical Center", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Northern Illinois Research Associates", "city": "DeKalb", "state": "Illinois", "zip": "60115", "country": "United States", "geoPoint": {"lat": 41.92947, "lon": -88.75036}}, {"facility": "Sneeze, Wheeze & Itch Associates LLC", "city": "Normal", "state": "Illinois", "zip": "61761", "country": "United States", "geoPoint": {"lat": 40.5142, "lon": -88.99063}}, {"facility": "Nassim, McMonigle, Mescia & Associates", "city": "New Albany", "state": "Indiana", "zip": "47150", "country": "United States", "geoPoint": {"lat": 38.28562, "lon": -85.82413}}, {"facility": "Grand Blanc Medical", "city": "Grand Blanc", "state": "Michigan", "zip": "48439", "country": "United States", "geoPoint": {"lat": 42.92753, "lon": -83.62995}}, {"facility": "Craig A. Spiegel MD", "city": "Bridgeton", "state": "Missouri", "zip": "63044", "country": "United States", "geoPoint": {"lat": 38.767, "lon": -90.41151}}, {"facility": "Midwest Allergy and Asthma center", "city": "Omaha", "state": "Nebraska", "zip": "68130", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "The Asthma & Allergy Center, P.C.", "city": "Papillion", "state": "Nebraska", "zip": "68046", "country": "United States", "geoPoint": {"lat": 41.15444, "lon": -96.04224}}, {"facility": "Maimonides Medical Center", "city": "Brooklyn", "state": "New York", "zip": "11219", "country": "United States", "geoPoint": {"lat": 40.6501, "lon": -73.94958}}, {"facility": "St. Elizabeth Health Center", "city": "Utica", "state": "New York", "zip": "13502", "country": "United States", "geoPoint": {"lat": 43.1009, "lon": -75.23266}}, {"facility": "Cincinnati Children's Hospital Medical Center", "city": "Cincinnati", "state": "Ohio", "zip": "45229", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Dayton Clinical Research", "city": "Dayton", "state": "Ohio", "zip": "45406", "country": "United States", "geoPoint": {"lat": 39.75895, "lon": -84.19161}}, {"facility": "Allergy, Asthma and clinical Research Center", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Eminence Research, LLC", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73139", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Asthma and Allergy Research Associates", "city": "Upland", "state": "Pennsylvania", "zip": "19013", "country": "United States", "geoPoint": {"lat": 39.85261, "lon": -75.38269}}, {"facility": "National Allergy, Asthma, and Uticaria Centers", "city": "Charleston", "state": "South Carolina", "zip": "29407", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "AAC Research - PC", "city": "Charleston", "state": "South Carolina", "zip": "29414", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "ADAC Research, PA", "city": "Greenville", "state": "South Carolina", "zip": "29607", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "The Asthma Institute, PLLC", "city": "Chattanooga", "state": "Tennessee", "zip": "37421", "country": "United States", "geoPoint": {"lat": 35.04563, "lon": -85.30968}}, {"facility": "Vanderbilt University Medical Center", "city": "Nashville", "state": "Tennessee", "zip": "37203", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "Isis Clinical Research, LLC", "city": "Austin", "state": "Texas", "zip": "78731", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Sirius Clinical Research, LLC", "city": "Austin", "state": "Texas", "zip": "78759", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Hill Country Family Medical Center", "city": "Boerne", "state": "Texas", "zip": "78006", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}, {"facility": "TTS Research", "city": "Boerne", "state": "Texas", "zip": "78006", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}, {"facility": "Allergy/Immunology Research Center of North Texas", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Dallas Allergy Immunology Research", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Western Sky Medical Research", "city": "El Paso", "state": "Texas", "zip": "79903", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Breath of Life Research Institute", "city": "Katy", "state": "Texas", "zip": "77450", "country": "United States", "geoPoint": {"lat": 29.78579, "lon": -95.8244}}, {"facility": "Live Oak Allergy and Asthma Clinic", "city": "Live Oak", "state": "Texas", "zip": "78233", "country": "United States", "geoPoint": {"lat": 29.56523, "lon": -98.3364}}, {"facility": "Quality Assurance Research Center, Inc.", "city": "San Antonio", "state": "Texas", "zip": "78205", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Southwest Allergy and Asthma, P.A.", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Sylvana Research Associates", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Allergy & Asthma Care of Waco", "city": "Waco", "state": "Texas", "zip": "76712", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "Allergy and Asthma Research Institute", "city": "Waco", "state": "Texas", "zip": "76712", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "PI-Coor Clinical Research, LLC", "city": "Burke", "state": "Virginia", "zip": "22015", "country": "United States", "geoPoint": {"lat": 38.79345, "lon": -77.27165}}, {"facility": "Colonial Heights Pediatrics", "city": "Colonial Heights", "state": "Virginia", "zip": "23834", "country": "United States", "geoPoint": {"lat": 37.26804, "lon": -77.40726}}, {"facility": "Bellingham Asthma, Allergy, & Immunology Clinic", "city": "Bellingham", "state": "Washington", "zip": "98225", "country": "United States", "geoPoint": {"lat": 48.75955, "lon": -122.48822}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Placebo", "description": "Placebo: Placebo (2 actuations)"}, {"id": "FG001", "title": "Levalbuterol MDI", "description": "90 ug Levalbuterol (2 actuations)\n\nLevalbuterol: 90 ug Levalbuterol (2 actuations)"}, {"id": "FG002", "title": "Levalbuterol UDV", "description": "0.31 ug Levalbuterol UDV TID\n\nLevalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "68"}, {"groupId": "FG001", "numSubjects": "65"}, {"groupId": "FG002", "numSubjects": "64"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "62"}, {"groupId": "FG001", "numSubjects": "60"}, {"groupId": "FG002", "numSubjects": "53"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "11"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Subject Uncooperative", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Noncompliance with Medication", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "One subject was randomized but not dosed in the Levalbuterol UDV arm.", "groups": [{"id": "BG000", "title": "Placebo", "description": "Placebo Placebo MDI TID"}, {"id": "BG001", "title": "Levalbuterol MDI", "description": "Levalbuterol MDI TID"}, {"id": "BG002", "title": "Levalbuterol UDV", "description": "Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "68"}, {"groupId": "BG001", "value": "65"}, {"groupId": "BG002", "value": "63"}, {"groupId": "BG003", "value": "196"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "68"}, {"groupId": "BG001", "value": "65"}, {"groupId": "BG002", "value": "63"}, {"groupId": "BG003", "value": "196"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Months", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "29.2", "spread": "12.17"}, {"groupId": "BG001", "value": "29.3", "spread": "12.57"}, {"groupId": "BG002", "value": "28.4", "spread": "12.48"}, {"groupId": "BG003", "value": "29.0", "spread": "12.35"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "0 to < 12 months", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "27"}]}]}, {"title": "0 to < 24 months", "categories": [{"measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "22"}, {"groupId": "BG003", "value": "68"}]}]}, {"title": "24 to < 48 months", "categories": [{"measurements": [{"groupId": "BG000", "value": "45"}, {"groupId": "BG001", "value": "42"}, {"groupId": "BG002", "value": "41"}, {"groupId": "BG003", "value": "128"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "35"}, {"groupId": "BG002", "value": "24"}, {"groupId": "BG003", "value": "88"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "39"}, {"groupId": "BG003", "value": "108"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "19"}, {"groupId": "BG003", "value": "56"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "52"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "44"}, {"groupId": "BG003", "value": "140"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "24"}, {"groupId": "BG003", "value": "65"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "39"}, {"groupId": "BG002", "value": "36"}, {"groupId": "BG003", "value": "121"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "8"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "68"}, {"groupId": "BG001", "value": "65"}, {"groupId": "BG002", "value": "63"}, {"groupId": "BG003", "value": "196"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline to Visit 4 in the Mean Daily Composite Score Based on the Pediatric Asthma Caregiver Assessments (PACA)", "description": "The daily composite score is the sum of the scores of 5 domains: Nocturnal Awakenings Due to Wheeze and Cough, Daytime Wheeze, Daytime Cough, Shortness of Breath, and Asthma Symptom Score. A possible score of 0 (no symptoms) to 19 (severe symptoms).\n\nThe mean daily composite score at Visit 4 is defined as the mean of the daily composite scores in the week prior to Visit 4.", "populationDescription": "Intent-to-Treat Population. Only those subjects who had non-missing data at Week 4 and at Baseline were included. Subjects who discontinued from the study prior to Week 4 are not included in this analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Visit 4 (Week 4)", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo: Placebo (2 actuations)"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "90 ug Levalbuterol (2 actuations)\n\nLevalbuterol: 90 ug Levalbuterol (2 actuations)"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "0.31 ug Levalbuterol UDV TID\n\nLevalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "54"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.21", "spread": "2.722"}, {"groupId": "OG001", "value": "-0.67", "spread": "2.092"}, {"groupId": "OG002", "value": "-0.52", "spread": "2.843"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "195 subjects were randomized in order to achieve 150 subjects completing the study. The sample size was set based on FDA requirements, and was outside of statistical considerations.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.54", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.412", "ciUpperLimit": "0.342", "estimateComment": "Difference is Placebo MDI minus Levalbuterol UDV"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "195 subjects were randomized in order to achieve 150 subjects completing the study. The sample size was set based on FDA requirements, and was outside of statistical considerations", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.69", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.714", "ciUpperLimit": "0.335", "estimateComment": "Difference is Levalbuterol UDV minus Levalbuterol MDI"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "195 subjects were randomized in order to achieve 150 subjects completing the study. The sample size was set based on FDA requirements, and was outside of statistical considerations.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.080", "ciUpperLimit": "0.771", "estimateComment": "Difference is Levalbuterol UDV minus Levalbuterol MDI"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Visit 3 in Mean Daily Composite Score Based on the Pediatric Asthma Caregiver Assessment", "description": "The daily composite score is the sum of the scores of 5 domains: Nocturnal Awakenings Due to Wheeze and Cough, Daytime Wheeze, Daytime Cough, Shortness of Breath, and Asthma Symptom Score. A possible score of 0 (no symptoms) to 19 (severe symptoms).\n\nThe mean daily composite score at Visit 3 is defined as the mean of the daily composite scores in the 7 days prior to Visit 3.", "populationDescription": "Intent-to-Treat Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Visit 3 (Week 3)", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "63"}, {"groupId": "OG002", "value": "56"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.83", "spread": "2.913"}, {"groupId": "OG001", "value": "-0.28", "spread": "2.490"}, {"groupId": "OG002", "value": "-0.22", "spread": "2.545"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Visit 2 to Visit 3 in the Mean Daily Composite Score Based on the Pediatric Asthma Caregiver Assessment", "description": "The daily composite score is the sum of the scores of 5 domains: Nocturnal Awakenings Due to Wheeze and Cough, Daytime Wheeze, Daytime Cough, Shortness of Breath, and Asthma Symptom Score. A possible score of 0 (no symptoms) to 19 (severe symptoms).\n\nThe mean daily composite score from Visit 2 to Visit 3 is defined as the mean of the daily composite scores from Visit 2 (inclusive) to the day prior to Visit 3.", "populationDescription": "Intent-to-Treat Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "The days from Visit 2 (inclusive) to the day prior to Visit 3 - approximately 14 days", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "LEV UDV 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "64"}, {"groupId": "OG002", "value": "59"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.82", "spread": "2.417"}, {"groupId": "OG001", "value": "-0.25", "spread": "2.041"}, {"groupId": "OG002", "value": "-0.15", "spread": "2.067"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Visit 3 to Visit 4 in the Mean Daily Composite Score Based on the Pediatric Asthma Caregiver Assessment", "description": "The daily composite score is the sum of the scores of 5 domains: Nocturnal Awakenings Due to Wheeze and Cough, Daytime Wheeze, Daytime Cough, Shortness of Breath, and Asthma Symptom Score. A possible score of 0 (no symptoms) to 19 (severe symptoms).\n\nThe mean daily composite score from Visit 3 to Visit 4 is defined as the mean of the daily composite scores from Visit 3 (inclusive) to the day prior to Visit 4.", "populationDescription": "Intent-to-Treat Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "The days from Visit 3 (inclusive) to the day prior to Visit 4 - approximately 14 days", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "LEV UDV 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "62"}, {"groupId": "OG002", "value": "57"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.08", "spread": "2.478"}, {"groupId": "OG001", "value": "-0.40", "spread": "2.285"}, {"groupId": "OG002", "value": "-0.52", "spread": "2.331"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Visit 3 in the Mean Daily Composite Score Based on the Daytime and Nighttime Asthma Symptom Scores as Measured by the Pediatric Asthma Questionnaire (PAQ)", "description": "The daily composite score is the sum of the scores of 7 items: Difficulty Breathing, Cough, Wheeze, Activity Limitation, Level of Activity Limitation, Overall Symptom Score, and Nighttime Asthma. The range for the PAQ is 0 (no symptoms) to 27 (severe symptoms).\n\nThe mean daily composite score at Visit 3 is defined as the mean daily composite scores for 7 days prior to Visit 3.", "populationDescription": "Intent-to-Treat Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Visit 3 (Week 3)", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI Placebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "63"}, {"groupId": "OG002", "value": "56"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.82", "spread": "3.457"}, {"groupId": "OG001", "value": "-0.45", "spread": "3.522"}, {"groupId": "OG002", "value": "0.00", "spread": "3.199"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Visit 4 in the Mean Daily Composite Score Based on the Daytime and Nighttime Asthma Symptom Scores as Measured by Pediatric Asthma Questionnaire", "description": "The daily composite score is the sum of the scores of 7 items: Difficulty Breathing, Cough, Wheeze, Activity Limitation, Level of Activity Limitation, Overall Symptom Score, and Nighttime Asthma. The range for the PAQ is 0 (no symptoms) to 27 (severe symptoms).\n\nThe mean daily composite score at Visit 4 is defined as the mean daily composite scores in the 7 days prior to Visit 4.", "populationDescription": "Intent-to-Treat Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, Visit 4 (Week 4)", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI Placebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "LEV UDV 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "54"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.39", "spread": "3.213"}, {"groupId": "OG001", "value": "-0.91", "spread": "2.585"}, {"groupId": "OG002", "value": "-0.47", "spread": "2.931"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Visit 2 to Visit 3 in the Mean Daily Composite Score Based on the Daytime and Nighttime Asthma Symptom Scores as Measured by the Pediatric Asthma Questionnaire", "description": "The daily composite score is the sum of the scores of 7 items: Difficulty Breathing, Cough, Wheeze, Activity Limitation, Level of Activity Limitation, Overall Symptom Score, and Nighttime Asthma. The range for the PAQ is 0 (no symptoms) to 27 (severe symptoms).\n\nThe mean daily composite score from Visit 2 to Visit 3 is defined as the mean of the daily composite scores from Visit 2 (inclusive) to the day prior to Visit 3.", "populationDescription": "Intent-to-Treat Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "The days from Visit 2 (inclusive) to the day prior to Visit 3 - approximately 14 days", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "59"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.87", "spread": "2.797"}, {"groupId": "OG001", "value": "-0.36", "spread": "2.872"}, {"groupId": "OG002", "value": "-0.08", "spread": "2.589"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Visit 3 to Visit 4 in the Mean Daily Composite Score Based on the Daytime and Nighttime Asthma Symptom Score as Measured by the Pediatric Asthma Questionnaire", "description": "The daily composite score is the sum of the scores of 7 items: Difficulty Breathing, Cough, Wheeze, Activity Limitation, Level of Activity Limitation, Overall Symptom Score, and Nighttime Asthma. The range for the PAQ is 0 (no symptoms) to 27 (severe symptoms).\n\nThe mean daily composite score from Visit 3 to Visit 4 is defined as the mean of the daily composite scores from Visit 3 (inclusive) to the day prior to Visit 4.", "populationDescription": "Intent-to-Treat Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "The days from Visit 3 (inclusive) to the day prior to Visit 4 - approximately 14 days", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "64"}, {"groupId": "OG001", "value": "62"}, {"groupId": "OG002", "value": "57"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.24", "spread": "2.979"}, {"groupId": "OG001", "value": "-0.61", "spread": "2.706"}, {"groupId": "OG002", "value": "-0.37", "spread": "2.572"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoints at Visit 2", "description": "Peak expiratory flow (PEF) measures how fast a person can breathe out using the greatest effort", "populationDescription": "Intent-to-Treat Population - PEF Cohort (Subjects able to perform PEFs)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Baseline, Visit 2: 30 minutes post-dose (on the day of randomization), 1 hour post-dose, 4 hours post-dose, 6 hours post-dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}]}], "classes": [{"title": "Visit 2, 30 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.08", "spread": "0.147"}, {"groupId": "OG001", "value": "0.17", "spread": "0.211"}, {"groupId": "OG002", "value": "0.16", "spread": "0.101"}]}]}, {"title": "Visit 2, 1 hour post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.04", "spread": "0.183"}, {"groupId": "OG001", "value": "0.13", "spread": "0.162"}, {"groupId": "OG002", "value": "0.18", "spread": "0.176"}]}]}, {"title": "Visit 2, 4 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.09", "spread": "0.303"}, {"groupId": "OG001", "value": "0.06", "spread": "0.098"}, {"groupId": "OG002", "value": "0.04", "spread": "0.188"}]}]}, {"title": "Visit 2, 6 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.07", "spread": "0.121"}, {"groupId": "OG001", "value": "0.12", "spread": "0.164"}, {"groupId": "OG002", "value": "0.06", "spread": "0.213"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoint at Visit 3", "populationDescription": "Intent-to-Treat Population - PEF Cohort (Subjects able to perform PEFs)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Baseline, Visit 3, pre-dose (approximately 14 days after randomization)", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.23", "spread": "0.255"}, {"groupId": "OG001", "value": "0.14", "spread": "0.251"}, {"groupId": "OG002", "value": "0.03", "spread": "0.120"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoint at Visit 4", "populationDescription": "Intent-to-Treat Population - PEF Cohort (Subjects able to perform PEFs)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Visit 4: pre-dose (approximately 28 days after randomization) , 30 minutes post-dose, 1 hour post-dose, 4 hours post-dose, 6 hours post-dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "8"}]}], "classes": [{"title": "Visit 4, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.25", "spread": "0.307"}, {"groupId": "OG001", "value": "0.29", "spread": "0.313"}, {"groupId": "OG002", "value": "0.04", "spread": "0.146"}]}]}, {"title": "Visit 4, 30 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.17", "spread": "0.323"}, {"groupId": "OG001", "value": "0.29", "spread": "0.247"}, {"groupId": "OG002", "value": "0.42", "spread": "0.585"}]}]}, {"title": "Visit 4, 1 hour post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.03", "spread": "0.332"}, {"groupId": "OG001", "value": "0.40", "spread": "0.242"}, {"groupId": "OG002", "value": "0.16", "spread": "0.227"}]}]}, {"title": "Visit 4, 4 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.11", "spread": "0.382"}, {"groupId": "OG001", "value": "0.30", "spread": "0.305"}, {"groupId": "OG002", "value": "0.11", "spread": "0.181"}]}]}, {"title": "Visit 4, 6 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.07", "spread": "0.260"}, {"groupId": "OG001", "value": "0.20", "spread": "0.173"}, {"groupId": "OG002", "value": "0.09", "spread": "0.361"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoints at Visit 2", "populationDescription": "Intent-to-Treat Population - PEF Cohort (Subjects able to perform PEFs)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Baseline, Visit 2: , 30 minutes post-dose (on the day of randomization), 1 hour post-dose, 4 hours post-dose, 6 hours post-dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "0.31 ug Levalbuterol UDV TID LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}]}], "classes": [{"title": "Visit 2, 30 minutes post-does", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.42", "spread": "9.940"}, {"groupId": "OG001", "value": "23.22", "spread": "36.195"}, {"groupId": "OG002", "value": "21.71", "spread": "23.782"}]}]}, {"title": "Visit 2, 1 hour post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.83", "spread": "15.094"}, {"groupId": "OG001", "value": "18.21", "spread": "26.225"}, {"groupId": "OG002", "value": "25.05", "spread": "37.207"}]}]}, {"title": "Visit 2, 4 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.22", "spread": "17.886"}, {"groupId": "OG001", "value": "9.54", "spread": "15.467"}, {"groupId": "OG002", "value": "11.74", "spread": "37.114"}]}]}, {"title": "Visit 2, 6 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.24", "spread": "10.440"}, {"groupId": "OG001", "value": "17.21", "spread": "24.013"}, {"groupId": "OG002", "value": "14.40", "spread": "41.548"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoints at Visit 3", "populationDescription": "Intent-to-Treat Population - PEF Cohort (Subjects able to perform PEFs)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Baseline, Visit 3, pre -dose (approximately 14 days after randomization)", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-18.58", "spread": "21.742"}, {"groupId": "OG001", "value": "25.36", "spread": "30.129"}, {"groupId": "OG002", "value": "6.02", "spread": "13.444"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in In-Clinic Peak Expiratory Flow to Postdose Timepoints at Visit 4", "populationDescription": "Intent-to-Treat Population - PEF Cohort (Subjects able to perform PEFs)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Baseline, Visit 4, pre -dose (approximately 28 days after randomization)", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "0.31 ug Levalbuterol UDV TID LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "8"}]}], "classes": [{"title": "Visit 4, pre-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-17.26", "spread": "23.343"}, {"groupId": "OG001", "value": "49.92", "spread": "48.545"}, {"groupId": "OG002", "value": "7.03", "spread": "18.829"}]}]}, {"title": "Visit 4, 30 minutes post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.69", "spread": "27.617"}, {"groupId": "OG001", "value": "48.94", "spread": "48.881"}, {"groupId": "OG002", "value": "47.47", "spread": "55.010"}]}]}, {"title": "Visit 4, 1 hour post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.94", "spread": "24.020"}, {"groupId": "OG001", "value": "63.76", "spread": "45.620"}, {"groupId": "OG002", "value": "25.32", "spread": "47.769"}]}]}, {"title": "Visit 4, 4 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.67", "spread": "27.435"}, {"groupId": "OG001", "value": "47.59", "spread": "42.339"}, {"groupId": "OG002", "value": "20.20", "spread": "37.895"}]}]}, {"title": "Visit 4, 6 hours post-dose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.06", "spread": "21.507"}, {"groupId": "OG001", "value": "32.00", "spread": "27.657"}, {"groupId": "OG002", "value": "25.09", "spread": "69.440"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the At-Home Mean Daily Peak Expiratory Flow (PEF to Postdose Timepoint at Visit 3 and Visit 4", "description": "Mean of the daily pre-dose PEF values in the week prior to visit in those subjects aged 24 to \\<48 months capable of performing acceptable and reproducible PEF maneuvers.", "populationDescription": "Intent-to-Treat Population - PEF Cohort (Subjects able to perform PEFs)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Baseline, Visit 3 (the week prior to Visit 3) and Visit 4", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "0.31 ug Levalbuterol UDV TID LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}]}], "classes": [{"title": "Visit 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.07", "spread": "0.164"}, {"groupId": "OG001", "value": "0.12", "spread": "0.209"}, {"groupId": "OG002", "value": "0.01", "spread": "0.193"}]}]}, {"title": "Visit 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "spread": "0.205"}, {"groupId": "OG001", "value": "0.08", "spread": "0.186"}, {"groupId": "OG002", "value": "-0.01", "spread": "0.096"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in the At-Home Mean Daily Peak Expiratory Flow (PEF to Postdose Timepoint at Visit 3 and Visit 4)", "description": "Mean of the daily pre-dose PEF values in the week prior to visit in those subjects aged 24 to \\<48 months capable of performing acceptable and reproducible PEF maneuvers.", "populationDescription": "Intent-to-Treat Population - PEF Cohort (Subjects able to perform PEFs)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Visit 3 (the week prior to Visit 3), Visit 4 (the week prior to Visit 4)", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "0.31 ug Levalbuterol UDV TID LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "8"}]}], "classes": [{"title": "Visit 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.39", "spread": "16.585"}, {"groupId": "OG001", "value": "15.05", "spread": "26.849"}, {"groupId": "OG002", "value": "5.30", "spread": "21.093"}]}]}, {"title": "Visit 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.21", "spread": "22.426"}, {"groupId": "OG001", "value": "10.33", "spread": "24.436"}, {"groupId": "OG002", "value": "-1.05", "spread": "12.155"}]}]}]}, {"type": "SECONDARY", "title": "Investigator Global Assessment - Question 1", "description": "Since the start of the study, how would you evaluate the child's asthma symptoms?", "populationDescription": "Intent-to-Treat Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of subjects", "timeFrame": "Visit 4 (End of 28 day treatment period)", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI Placebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "55"}]}], "classes": [{"title": "Much Better", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "16"}]}]}, {"title": "Moderately Better", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "13"}]}]}, {"title": "Slightly Better", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "11"}]}]}, {"title": "The Same", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "13"}]}]}, {"title": "Slightly Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Moderately Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Much Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Investigator Global Assessment - Question 2", "description": "Since the start of the study, how would you evaluate your ability to manage the subject's asthma?", "populationDescription": "Intent-to-Treat Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of subjects", "timeFrame": "Visit 4 (End of 28 day treatment period)", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "0.31 ug Levalbuterol UDV TID LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "55"}]}], "classes": [{"title": "Much Better", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "23"}]}]}, {"title": "Moderately Better", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "11"}]}]}, {"title": "Slightly Better", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "7"}]}]}, {"title": "The Same", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "14"}]}]}, {"title": "Slightly Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Moderately Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Much Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Caregiver Global Assessment - Question 1", "description": "Since the start of the study, how would you evaluate your child's asthma symptoms?", "populationDescription": "Intent-to-Treat Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of subjects", "timeFrame": "Visit 4 (End of 28 day treatment period)", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "0.31 ug Levalbuterol UDV TID LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "55"}]}], "classes": [{"title": "Much Better", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "21"}]}]}, {"title": "Moderately Better", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "13"}]}]}, {"title": "Slightly Better", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "8"}]}]}, {"title": "The Same", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "12"}]}]}, {"title": "Slightly Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Moderately Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Much Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Caregiver Global Assessment - Question 2", "description": "Since the start of the study, how would you evaluate your ability to manage your child's asthma?", "populationDescription": "Intent-to-Treat Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of subjects", "timeFrame": "Visit 4 (End of 28 day treatment period)", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI Placebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "0.31 ug Levalbuterol UDV TID LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "55"}]}], "classes": [{"title": "Much Better", "categories": [{"measurements": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "32"}, {"groupId": "OG002", "value": "29"}]}]}, {"title": "Moderately Better", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "10"}]}]}, {"title": "Slightly Better", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "The Same", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}]}]}, {"title": "Slightly Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Moderately Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Much Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Caregiver Global Assessment - Question 3", "description": "Overall I was: Very satisfied with the control of the child's asthma symptoms while enrolled in this study, Moderately satisfied with the control of the child's asthma symptoms while enrolled in this study, Slightly satisfied with the control of the child's asthma symptoms while enrolled in this study, Not satisfied with the control of the child's asthma symptoms while enrolled in this study or answer Missing", "populationDescription": "Intent-to-Treat Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of subjects", "timeFrame": "Visit 4 (End of 28 day treatment period)", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "0.31 ug Levalbuterol UDV TID LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "55"}]}], "classes": [{"title": "Very satisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "47"}, {"groupId": "OG001", "value": "45"}, {"groupId": "OG002", "value": "45"}]}]}, {"title": "Moderately satisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "7"}]}]}, {"title": "Slightly satisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Not satisfied", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Rescue Medication Use: Number of Subjects Using Rescue Medication During the Treatment Period", "description": "Number of subjects using rescue medication during the treatment period", "populationDescription": "Intent-to-Treat Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of subjects", "timeFrame": "Visit 2 to Visit 3 (the first 2 weeks of the study) , Visit 3 to Visit 4 (the second 2 weeks of the study), Visit 2 to Visit 4 (the entire 4 weeks of the study)", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "63"}]}], "classes": [{"title": "Visit 2 to Visit 3 the first 2 weeks of the study", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "20"}, {"groupId": "OG002", "value": "14"}]}]}, {"title": "Visit 3 to Visit 4 the second 2 weeks of the study", "categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "20"}, {"groupId": "OG002", "value": "12"}]}]}, {"title": "Visit 2 to Visit 4 the entire 4 weeks of the study", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "29"}, {"groupId": "OG002", "value": "20"}]}]}]}, {"type": "SECONDARY", "title": "Rescue Medication Use - Change From Baseline in Mean Number of Days Used Per Week When Used", "populationDescription": "Intent-to-Treat Population - Subjects who used rescue medication at any time during the first two weeks of the study and who used rescue medication at any time during baseline", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Days per Week", "timeFrame": "Visit 2 to Visit 3 (the first 2 weeks of the study) , Visit 3 to Visit 4 (the second 2 weeks of the study), Visit 2 to Visit 4 (the entire 4 weeks of the study)", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "0.31 ug Levalbuterol UDV TID LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "3"}]}], "classes": [{"title": "Visit 2 to Visit 3 the first 2 weeks of the study", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "2.43"}, {"groupId": "OG001", "value": "-0.8", "spread": "2.22"}, {"groupId": "OG002", "value": "-1.3", "spread": "1.29"}]}]}, {"title": "Visit 3 to Visit 4 the second 2 weeks of the study", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "1.51"}, {"groupId": "OG001", "value": "0.1", "spread": "2.57"}, {"groupId": "OG002", "value": "-1.0", "spread": "0.94"}]}]}, {"title": "Visit 2 to Visit 4 the entire 4 weeks of the study", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "1.95"}, {"groupId": "OG001", "value": "-0.5", "spread": "1.89"}, {"groupId": "OG002", "value": "-1.1", "spread": "0.73"}]}]}]}, {"type": "SECONDARY", "title": "Rescue Medication Use - Change From Baseline in Mean Number of Doses Used Per Week", "populationDescription": "Intent-to-Treat Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Doses per Week", "timeFrame": "Visit 2 to Visit 3 (the first 2 weeks of the study) , Visit 3 to Visit 4 (the second 2 weeks of the study), Visit 2 to Visit 4 (the entire 4 weeks of the study)", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "65"}, {"groupId": "OG002", "value": "63"}]}], "classes": [{"title": "Visit 2 to Visit 3 the first 2 weeks of the study", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "3.14"}, {"groupId": "OG001", "value": "0.1", "spread": "2.77"}, {"groupId": "OG002", "value": "0.0", "spread": "0.77"}]}]}, {"title": "Visit 3 to Visit 4 the second 2 weeks of the study", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "3.56"}, {"groupId": "OG001", "value": "0.4", "spread": "2.83"}, {"groupId": "OG002", "value": "0.1", "spread": "1.28"}]}]}, {"title": "Visit 2 to Visit 4 the entire 4 weeks of the study", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "3.10"}, {"groupId": "OG001", "value": "0.3", "spread": "2.23"}, {"groupId": "OG002", "value": "0.0", "spread": "0.96"}]}]}]}, {"type": "SECONDARY", "title": "Rescue Medication Use - Change From Baseline in Mean Number of Doses Used Per Week During Weeks When Used", "populationDescription": "Intent-to-Treat Population - subjects who used rescue medication at any time during the first 2 weeks of the study and who had used rescue medication at any time during baseline", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Doses per Week", "timeFrame": "Visit 2 to Visit 3 (the first 2 weeks of the study), Visit 3 to Visit 4 (the second 2 weeks of the study), Visit 2 to Visit 4 (the entire 4 weeks of the study)", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "0.31 ug Levalbuterol UDV TID LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "3"}]}], "classes": [{"title": "Visit 2 to Visit 3 the first 2 weeks of the study", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.1", "spread": "8.84"}, {"groupId": "OG001", "value": "-0.6", "spread": "3.94"}, {"groupId": "OG002", "value": "-1.3", "spread": "2.08"}]}]}, {"title": "Visit 3 to Visit 4 the second 2 weeks of the study", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.9", "spread": "7.64"}, {"groupId": "OG001", "value": "2.8", "spread": "6.27"}, {"groupId": "OG002", "value": "-0.8", "spread": "1.44"}]}]}, {"title": "Visit 2 to Visit 4 the entire 4 weeks of the study", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.1", "spread": "8.06"}, {"groupId": "OG001", "value": "1.8", "spread": "4.75"}, {"groupId": "OG002", "value": "-0.8", "spread": "1.56"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Visit 3 and Visit 4 in the Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLA) Composite Score", "description": "The PACQLQ composite score was calculated as the mean of the scores of the 13 individual questions. Composite scores could range from 1 to 7. Lower scores indicated greater impact of disease on quality of life.", "populationDescription": "Intent-to-Treat Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Units on a scale", "timeFrame": "Visit 3 and Visit 4 (End of 28 day treatment period)", "groups": [{"id": "OG000", "title": "Placebo", "description": "PBO MDI\n\nPlacebo: Placebo (2 actuations) MDI TID"}, {"id": "OG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID"}, {"id": "OG002", "title": "Levalbuterol UDV", "description": "0.31 ug Levalbuterol UDV TID LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "55"}]}], "classes": [{"title": "Visit 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.34", "spread": "0.888"}, {"groupId": "OG001", "value": "0.35", "spread": "0.976"}, {"groupId": "OG002", "value": "0.18", "spread": "0.944"}]}]}, {"title": "Visit 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.41", "spread": "0.931"}, {"groupId": "OG001", "value": "0.44", "spread": "1.171"}, {"groupId": "OG002", "value": "0.21", "spread": "0.883"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "4 weeks", "description": "One subject in the randomized to levalbuterol UDV group was not dosed", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "PBO MDI Placebo: Placebo (2 actuations) MDI TID", "seriousNumAffected": 0, "seriousNumAtRisk": 68, "otherNumAffected": 28, "otherNumAtRisk": 68}, {"id": "EG001", "title": "Levalbuterol MDI", "description": "LEV MDI Levalbuterol: 90 ug Levalbuterol (2 actuations) MDI TID", "seriousNumAffected": 1, "seriousNumAtRisk": 65, "otherNumAffected": 31, "otherNumAtRisk": 65}, {"id": "EG002", "title": "Levalbuterol UDV", "description": "LEV UDV Levalbuterol UDV TID: 0.31 ug Levalbuterol UDV TID", "seriousNumAffected": 3, "seriousNumAtRisk": 63, "otherNumAffected": 27, "otherNumAtRisk": 63}], "seriousEvents": [{"term": "Metapneumovirus Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 63}]}, {"term": "Hypoxia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Status Asthmaticus", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}], "otherEvents": [{"term": "Abdominal Pain Upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 63}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Sinusitis Bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Dermatitis Diaper", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 8, "numAffected": 6, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 63}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 7, "numAffected": 7, "numAtRisk": 63}]}, {"term": "Otitis Media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 8, "numAffected": 8, "numAtRisk": 63}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 63}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 63}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 68}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 65}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish"}, "pointOfContact": {"title": "Respiratory Medical Director", "organization": "Sunovion", "phone": "1-866-503-6351"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000420", "term": "Albuterol"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "asFound": "APD", "relevance": "HIGH"}, {"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}]}}, "hasResults": true}